An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
← catalyst calendarNCT06035120 · readout in 315 d
Sponsored by Pulmonx Corporation (industry) · LUNG — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
200estimated
Sites
36
Countries
Australia, Austria, Denmark +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-22 | actual | When the study began enrolling |
| Primary completion | 2027-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Emphysema, Pulmonary
- Emphysema or COPD
Intervention
- Device: AeriSeal System
Primary outcome
what the primary-completion date above is the date OFConverters, responder rate
measured 45 days post-AeriSeal treatment (index or repeat)
Permalink · LUNG's whole pipeline · Catalyst calendar · Every registered study · What changed